Univercells strives to bring a fundamental change to the biomanufacturing industry with the ambition to make biologics (e.g. viral vaccines, monoclonal antibodies) available and affordable to all by reinventing bioprocess architecture. This ambition embodies the industry paradigm shift, from a centralized manufacturing model to distributed manufacturing, where local production facilities could supply local populations with affordable treatments.

For this purpose, Univercells has developed an innovative manufacturing platform based on a disruptive setup, with improvements introduced at each step of the manufacturing process. Bioproduction intensification and integration results in a drastic reduction of the size of the manufacturing facility, while optimizing its performance.

This highly innovative technology platform allows Univercells to rapidly deploy autonomous multi-product micro-facilities, more cost-effective to build (drastic CAPEX reduction) and to operate (significantly lower OPEX), while offering flexible capabilities.

Our business model is to collaborate with:

  • Small to medium companies to deploy their own cost-effective autonomous production capacities in less than 2 years;
  • Established large pharma companies willing to revamp their legacy product portfolio to develop a competitive offer to emerging markets.


The shift to biosimilars has seen the emergence of leaders defying current barriers to enter bioindustries : huge investment, high operational costs and complex process operations. Univercells team draw on its experience in every aspect of bioproduction to help the leaders who have the ambition to change the paradigm.

We completely rethink single-use bioprocesses to minimize footprint and unit cost while simplifying operations. We integrate unit operations (a benchmark in many industries for decades), which dramatically drives cost down. And we design manufacturing facilities ”around” optimized integrated processes. This is how we implement biomanufacturing solutions enabling production capacities that will make biologics accessible to all.

We believe in technology-driven affordability, independently of the place, country or continent where the facility is implemented. Driven by effectuation and operational agility, we can manage selected parts of your industrialization plan or we can take care of your biomanufacturing project, from A to Z.